administered to patients with type 2 diabetes improved the acute insulin and C-peptide responses to glucose as estimated by the intravenous glucose tolerance test [3] . Also, Balas et al. showed that single administration of vildagliptin augmented insulin secretion and inhibited glucagon release, leading to enhanced suppression of endogenous glucose production during MTT, as estimated using the double tracer technique [4] . Although the oral glucose tolerance test (OGTT) is simpler, less time-consuming and less expensive to perform than the intravenous or tracer tests, and is often used in intervention studies, the efficacy of vildagliptin has not yet been adequately examined by OGTT. These conditions prompted us to investigate the factors that might contribute to the glucose-lowering effect of vildagliptin by analyzing the results of OGTT together with several clinical parameters in Japanese patients with type 2 diabetes before and after 24 weeks of treatment with vildagliptin.
2-sided, and values less than 0.05 were considered to be statistically significant.
Results
A total of 15 patients were recruited. Of these, the examinations could not be completed satisfactorily in 2 patients. The data of the remaining 13 patients were included in the analysis. Out of the 13 patients, 8 were men and 5 were women. The mean age was 68.9 ± 6.7 years. At baseline, the mean fasting plasma glucose (FPG) was 156.9 ± 39.0 mg/dL, and the mean HbA1c was 7.2 ± 0.5%. The average duration of diabetes was 6.3 ± 5.7 years, and the mean body mass index (BMI) was 22.4 ± 3.3 kg/m 2 . Of the 13 subjects, 4 were treated with vildagliptin alone, and 4 received vildagliptin together with a sulfonylurea; the remaining were treated with vildagliptin in place of an alpha-glucosidase inhibitor (n = 2), glinide (n = 1), or a combination of an alphaglucosidase inhibitor and a glinide (n = 2). After 24 weeks, the FPG decreased to 136.5 ± 34.9 mg/dL and the HbA1c decreased to 6.9 ± 0.7%, with no significant increase of the body weight (Before treatment: 57.7 ± 11.8 kg, After treatment: 57.5 ± 11.3 kg).
When these results were analyzed in detail, we noted the existence of responders and non-responders: the responders consisting of subjects whose HbA1c decreased following 24 weeks treatment with vildagliptin, and the non-responders consisting of subjects who did not show any significant decrease of the HbA1c. Therefore, we analyzed the results by dividing the entire subject population into the responder and non-responder groups; after 24 weeks of treatment with vildagliptin, 4 (30.8%) patients were classified into the non-responder group. Before the start of treatment with vildagliptin, there were no differences in the baseline characteristics (Table 1) or the breakdown of other oral hypoglycemic medication (data not shown) between the two groups. After 24 weeks of treatment, HbA1c was significantly reduced from 7.3 ± 0.5% to 6.7 ± 0.5% in the responder group (P = 0.0077), while it tended to rather increase from 7.1 ± 0.6% to 7.5 ± 0.7% in the non-responder group (P = 0.0679). There were no differences in the degree of change of the body weight between the two groups (Before treatment: 56.8 ± 13.3 kg in the responder group; 59.7 ± 8.9 kg in the non-responder group, After treatment: 56.9 ± 13.1 kg in the responder group; 58.9 ± 7.5 kg in the non-responder group).
Materials and Methods
Japanese type 2 diabetic patients over 20 years of age, who visited the outpatient clinic of the Yokohama City University Hospital or Kanagawa Cardiovascular and Respiratory Center, were recruited into the present study. The study was conducted with the approval of the institutional review board and written informed consent from the patients was obtained from all patients. Type 2 diabetes was diagnosed in accordance with the criteria proposed by the Japan Diabetes Society (JDS) [5] . The exclusion criteria were type 1 diabetes and patients receiving insulin therapy or already receiving DPP-4 inhibitor treatment. Other exclusion criteria were pregnancy, possible pregnancy and lactation. A history of severe hepatic dysfunction was also considered as an exclusion criterion.
We analyzed several clinical parameters, including HbA1c and body weight before and after 24 weeks of treatment with vildagliptin at 100 mg/day. Also, the plasma glucose and insulin were measured after an overnight 12-h fast and during a 75-g OGTT at 30, 60, 90 and 120 min before and after 24 weeks of treatment with vildagliptin. On the day of the OGTT, the medication before the OGTT was withheld. The HbA1c (%) value was estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value (%) calculated by using the formula: HbA1c (%) = HbA1c (JDS) (%) + 0.4 %, considering the relational expression of HbA1c (JDS) (%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP) [5] . Insulin sensitivity was estimated by the use of the Matsuda index [6] and homeostasis model assessment of insulin resistance (HOMA-IR) [7] . Glucosestimulated insulin secretion was evaluated based on the insulinogenic index [8], oral disposition index [9] , the insulin-to-glucose ratio determined 30 min after the glucose load (insulin/glucose 30 min) [10] and homeostasis model assessment of the beta cell function (HOMA-β) [7] . In the present study, the oral disposition index was calculated as the product of Matsuda index and insulinogenic index.
Results are expressed as means ± SD. Differences between the responder group and the non-responder group were analyzed for statistical significance by the Mann-Whitney U-test for unpaired comparisons. Paired analyses within groups were conducted using Wilcoxon's signed-rank test. All P values were oral disposition index after vildagliptin treatment were significantly higher in the responder group than in the non-responder group. By contrast, the insulin/glucose ratio at 30 min and the HOMA-β were indistinguishable between the two groups after vildagliptin treatment.
Discussion
In this study, 69.2% of the patients classified as responders, were found to show improved glucose tolerance following treatment with 100 mg vildagliptin daily for 24 weeks. Moreover, the glucose-stimulated insulin secretion as estimated by the insulinogenic index and oral disposition index after treatment with vildagliptin were significantly higher in the responder group than in the non-responder group, whereas the insulin sensitivity as estimated by the Matsuda index and HOMA-IR were similar between the two groups. Since there were no differences in the baseline characteristics or any parameters estimated by the OGTT between the two groups before administration of vildagliptin, we assume that the difference in the degree of improvement of the glucose tolerance between the two groups could be associated with the effect of vildagliptin on the glucose-stimulated insulin secretion, which could not be predicted from the data before the start of vildagliptin administration. Then, what explains this phenomenon? We assume that genetic variations could have some influence on the difference between the two groups, since it has been reported that variations of the GLP1R, which encodes the GLP-1 receptor, may be associated with altered insulin secretion in response to GLP-1 [11] .
Decreased insulin secretion might be induced not only by functional defects of the beta cells, but also by the loss of beta cell mass. Reduction of the beta cell mass has been shown in patients with type 2 diabetes [12] . Since we recently demonstrated that vildagliptin increased the beta cell mass in a diabetic mouse model [13] , we compared the insulin/glucose ratio at 30 min, which reportedly is a better predictor of the beta cell mass [10] , between the two groups; however, there was no difference in this ratio between the two groups. This could be explained to be a result of the duration of vildagliptin treatment being too short, because the increased beta cell secretory capacity following daily treatment with 100 mg vildagliptin even for 52 weeks was not maintained after the washout, indicating that this increased capacity may not have a diseaseNext, we compared several parameters, including the insulin secretion and insulin sensitivity as estimated by the OGTT between the responder group and the nonresponder group before and after 24 weeks of treatment with vildagliptin (Table 2 ). There were no differences in these parameters between the two groups before the start of administration of vildagliptin. After vildagliptin treatment, glucose Σ0-120 min was significantly lower in the responder group than in the non-responder group. Although the Matsuda index and HOMA-IR were similar in the two groups after treatment with vildagliptin, the insulinogenic index and Values are means ± SD. * P < 0.05; ** P < 0.01 vs. pre modifying effect on the beta cell mass [14] . Also, it is necessary to set a sufficient period for washout to estimate the beta cell mass. Further study is needed over a longer duration of treatment and setting a sufficient period for washout.
The problem point of our results is whether improved glucose-stimulated insulin secretion could be a cause for the amelioration of hyperglycemia, or a result of this. Indeed, since it has been reported that vildagliptin treatment improved glucose-stimulated insulin secretion in patients with type 2 diabetes [3] , we assume that improved glucose-stimulated insulin secretion could be a cause for the glycemic improvement. However, since it has also been reported that early-phase insulin release was significantly decreased in the diabetic range of FPG and 2-h plasma glucose estimated by OGTT [15] , it could not be ruled out that improved glucosestimulated insulin secretion was a result. Although there is no correlation between the insulinogenic index or oral disposition index and FPG or 2-h plasma glucose estimated by the OGTT in our study (data not shown), it might be due to a small sample. At this time, we could not clarify the problem point.
The limitations of our study were the relatively small sample and lack of a placebo group. Also, there was the limitation of the assessment by the OGTT. Although the oral route of glucose delivery is more physiological than intravenous glucose infusion, the OGTT results are poorly reducible on account of variations in the glucose absorption and splanchnic glucose uptake [16] . However, OGTT is a simpler and less expensive test method that provides reasonably reliable estimates of insulin secretion and insulin sensitivity. Further large-scale randomized controlled studies are needed to obtain more detailed information.
In conclusion, our results suggest that the difference in the degree of improvement of the glucose tolerance between the responder group and non-responder group in this study could be associated with the effect of vildagliptin on the glucose-stimulated insulin secretion, but not on the insulin sensitivity.
